HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer

Andrew E. Teschendorff, Shih Han Lee, Allison Jones, Heidi Fiegl, Marie Kalwa, Wolfgang Wagner, Kantaraja Chindera, Iona Evans, Louis Dubeau, Arturo Orjalo, Hugo M. Horlings, Lukas Niederreiter, Arthur Kaser, Winnie Yang, Ellen L. Goode, Brooke L. Fridley, Richard G. Jenner, Els M.J.J. Berns, Elisabeth Wik, Helga B. SalvesenG. Bea A. Wisman, Ate G.J. van der Zee, Ben Davidson, Claes G. Trope, Sandrina Lambrechts, Ignace Vergote, Hilary Calvert, Ian J. Jacobs, Martin Widschwendter

Research output: Contribution to journalArticle

95 Scopus citations

Abstract

Background: Understanding carboplatin resistance in ovarian cancer is critical for the improvement of patients' lives. Multipotent mesenchymal stem cells or an aggravated epithelial to mesenchymal transition phenotype of a cancer are integrally involved in pathways conferring chemo-resistance. Long non-coding RNA HOTAIR (HOX transcript antisense intergenic RNA) is involved in mesenchymal stem cell fate and cancer biology. Methods: We analyzed HOTAIR expression and associated surrogate DNA methylation (DNAme) in 134 primary ovarian cancer cases (63 received carboplatin, 55 received cisplatin and 16 no chemotherapy). We validated our findings by HOTAIR expression and DNAme analysis in a multicentre setting of five additional sets, encompassing 946 ovarian cancers. Chemo-sensitivity has been assessed in cell culture experiments. Results: HOTAIR expression was significantly associated with poor survival in carboplatin-treated patients with adjusted hazard ratios for death of 3.64 (95 % confidence interval [CI] 1.78-7.42; P < 0.001) in the discovery and 1.63 (95 % CI 1.04-2.56; P = 0.032) in the validation set. This effect was not seen in patients who did not receive carboplatin (0.97 [95 % CI 0.52-1.80; P = 0.932]). HOTAIR expression or its surrogate DNAme signature predicted poor outcome in all additional sets of carboplatin-treated ovarian cancer patients while HOTAIR expressors responded preferentially to cisplatin (multivariate interaction P = 0.008). Conclusions: Non-coding RNA HOTAIR or its more stable DNAme surrogate may indicate the presence of a subset of cells which confer resistance to carboplatin and can serve as (1) a marker to personalise treatment and (2) a novel target to overcome carboplatin resistance.

Original languageEnglish (US)
Article number108
JournalGenome medicine
Volume7
Issue number1
DOIs
StatePublished - Oct 24 2015

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Teschendorff, A. E., Lee, S. H., Jones, A., Fiegl, H., Kalwa, M., Wagner, W., Chindera, K., Evans, I., Dubeau, L., Orjalo, A., Horlings, H. M., Niederreiter, L., Kaser, A., Yang, W., Goode, E. L., Fridley, B. L., Jenner, R. G., Berns, E. M. J. J., Wik, E., ... Widschwendter, M. (2015). HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome medicine, 7(1), [108]. https://doi.org/10.1186/s13073-015-0233-4